The study will begin with 20 non-Hodgkin lymphoma patients who have failed standard therapy. Each study participant will be given varied intravenous doses of vitamin C three times a week. The patients will be evaluated and monitored for progression of their disease. The studys goals are to show diminished progression of the disease in participating patients.
As leaders in the field of integrative medicine, Jefferson is always seeking new and innovative therapies for our patients, concluded Monti. We want to look in every corner for solutions. This study is a unique collaboration of several clinical and research specialists. If this study yields positive data we will do further studies to expand the availability of this intriguing therapy.
'/>"/>
| Contact: Rick Cushman richard.cushman@jefferson.edu 215-955-2240 Thomas Jefferson University Source:Eurekalert |